XML 45 R24.htm IDEA: XBRL DOCUMENT v3.21.1
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2020
Income Tax Disclosure [Abstract]  
Schedule of Effective Income Tax Rate of Company and Subsidiaries [Table Text Block]

As a result of the Reorganization described in Note 1, the Company is taxed according to U.S. federal and state tax laws and Israeli tax laws. The statutory tax rates applicable to the income of the Company and its subsidiaries are as follows:

 

 

 

Year Ended December 31,

 

 

 

2020

 

 

2019

 

89bio, Inc.

 

 

21

%

 

 

21

%

89Bio Ltd

 

 

23

%

 

 

23

%

89bio Management, Inc.

 

 

21

%

 

 

21

%

UAB 89bio Lithuania

 

 

15

%

 

 

15

%

Summary of Income Tax Benefit (Expense)

The income tax benefit (expense) is comprised of (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2020

 

 

2019

 

Current:

 

 

 

 

 

 

 

 

Federal

 

$

(11

)

 

$

(167

)

State

 

 

1

 

 

 

(1

)

Foreign

 

 

 

 

 

(30

)

Total

 

 

(10

)

 

 

(198

)

 

 

 

 

 

 

 

 

 

Deferred:

 

 

 

 

 

 

 

 

Federal

 

 

69

 

 

 

(20

)

Total

 

 

69

 

 

 

(20

)

Income tax benefit (expense)

 

$

59

 

 

$

(218

)

Summary of Components of Deferred Tax Assets Significant components of the Company’s deferred tax assets are as follows (in thousands):

 

 

 

As of December 31,

 

 

 

2020

 

 

2019

 

U.S. net operating loss carryforwards

 

$

11,342

 

 

$

1,916

 

Israel net operating loss carryforwards

 

 

3,978

 

 

 

4,328

 

Research and development expenses

 

 

5,392

 

 

 

3,419

 

Accrued expenses

 

 

635

 

 

 

349

 

Other

 

 

658

 

 

 

10

 

Total deferred tax assets

 

 

22,005

 

 

 

10,022

 

Less: valuation allowance

 

 

(21,936

)

 

 

(10,022

)

Net deferred tax assets

 

$

69

 

 

$

 

 

Summary of Loss from Continuing Operations Before Taxes on Income

The Company recorded a loss from continuing operations, before income tax for the periods indicated as follows (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2020

 

 

2019

 

United States

 

$

(58,760

)

 

$

(19,502

)

Lithuania

 

 

(73

)

 

 

200

 

Israel

 

 

9,275

 

 

 

(37,900

)

Net loss before income tax

 

$

(49,558

)

 

$

(57,202

)

Summary of Reconciliation of Income Tax Benefit (Expense) Statutory Tax Rate to Effective Tax Rate

The reconciliation of income tax benefit (expense) based on the statutory tax rate to the effective tax rate is as follows (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2020

 

 

2019

 

Income tax benefit computed at statutory rates

 

$

8,285

 

 

$

13,095

 

Research and development credits, net of

  uncertain tax position

 

 

815

 

 

 

93

 

Change in valuation allowance

 

 

(11,914

)

 

 

(6,520

)

Change in Israel effective tax rate due to the 2019

   reorganization

 

 

647

 

 

 

(734

)

Foreign rate differential

 

 

1,671

 

 

 

 

Revaluation of convertible preferred stock liability

 

 

 

 

 

(6,039

)

Other

 

 

555

 

 

 

(113

)

Income tax benefit (expense)

 

$

59

 

 

$

(218

)